Clinical laboratories certified under Clinical Laboratory Improvement Amendments can immediately begin using this kit to detect SARS-CoV-2, the virus that causes COVID-19.
PerkinElmer's RT-PCR test is marketed as an in vitro diagnostic device by meeting the requirements of the European In Vitro Diagnostic Directive and is available in over 30 countries worldwide.
PerkinElmer offers solutions to serve the diagnostics, life sciences, food and applied markets.
The company reported revenue of approximately USD 2.9bn in 2019, serves customers in 190 countries, and is a component of the S and P 500 index.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval